GSK PLC ADR (GSK) News
Filter GSK News Items
GSK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GSK News Highlights
- For GSK, its 30 day story count is now at 21.
- Over the past 14 days, the trend for GSK's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG, AGE and HEAR are the most mentioned tickers in articles about GSK.
Latest GSK News From Around the Web
Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.
Top Pharmaceutical Stocks for Q2 2023Aclaris Therapeutics, Collegium Pharmaceutical, and Intra-Cellular Therapies lead the industry in quarterly revenue growth |
UPDATE 2-US FDA panel backs Pfizer's maternal RSV vaccine for protecting infantsAdvisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness. The FDA's advisory committee voted unanimously that available data supported the vaccine's efficacy for giving the shot to women in their second or third trimesters of pregnancy to prevent lower respiratory tract infection and severe disease in infants up to 6 months of age. The expert panel voted 10-4 that the data also supports the safety of the vaccine for that patient population, paving the way for likely U.S. approval. |
25 Most Prescribed Medication in the WorldIn this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see the 10 most prescribed medication in the world. The advancements that the medical field has accomplished over the past century, and especially in recent decades, has […] |
US FDA advisers to discuss Pfizer's maternal RSV vaccineAdvisers to the U.S. Food and Drug Administration on Thursday will discuss Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers. An estimated 58,000 to 80,000 children under 5 years old are hospitalized due to RSV infection annually in the United States, according to government data. The agency's staff reviewers on Tuesday deemed the safety data for Pfizer's vaccine "generally favorable". |
India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing capsIndia's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines. Consolidated profit before tax dropped to 1.90 billion rupees ($23.23 million) for the quarter ended March 31, from 2.08 billion rupees a year earlier, the Indian unit of UK's GSK Plc said in an exchange filing. Revenue from operations at the maker of Augmentin antibiotic and T-Bact ointment fell 2.7% to 7.87 billion rupees. |
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK AcquisitionMONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl |
3 Personalized Medicine Stocks to Buy for Long-Time ReturnsPersonalized medicine is the future of medicine. |
UPDATE 3-US Supreme Court rejects Teva challenge to $235 million GSK award in patent disputeThe U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug. |
US Supreme Court rejects Teva challenge to $235 million GSK award in patent disputeThe U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug. |
These 3 Global Drug Stocks Have a Prescription for High YieldsLet's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields. |